


New Study Shows PBMs Reduce Spending in Medicare Part D, Driving Down Costs for Beneficiaries, Taxpayers

A new study released by the Coalition for Affordable Prescription Drugs (CAPD) and conducted by Oliver Wyman provides the most comprehensive look to-date at the savings generated by PBMs in the Medicare Part D program. Oliver Wyman estimates PBMs saved the Part D program **\$47 billion** in 2014 and projects savings of **\$896 billion** over ten years, from 2016 to 2025.

PBMs ARE PROJECTED TO SAVE MEDICARE PART D...



OTHER KEY FINDINGS

- > Without PBMs, Part D costs would be **58 percent higher** and beneficiary premiums would be **66 percent higher**.
- > PBMs are projected to save CMS and Part D beneficiaries on average \$153.81 per enrollee, per month over the 2016-2025 period, which translates to more than **\$1,800 per enrollee, per year**.

“PBMs are generating significant savings for the government, taxpayers, and beneficiaries in the Medicare Part D program. These savings are a result of PBMs’ use of clinical programs and negotiating experience, ensuring more affordable access to prescription drugs for seniors, better health outcomes, and more value. This study demonstrates that PBMs’ role in the Part D program is working for the government, taxpayers, and beneficiaries. Policymakers should build on this proven private sector solution.”

– CAPD EXECUTIVE DIRECTOR **MEGHAN SCOTT**

Learn more at affordableprescriptiondrugs.org